Diagnostic Approach for Suspected Alcohol Cirrhosis

Initial Evaluation

The European Association for the Study of the Liver recommends documenting regular alcohol consumption of >30 g/day in males or >20 g/day in females, typically for >5 years, to assess alcohol exposure history 1, 2
Assess for extrahepatic manifestations including symmetric peripheral neuropathy, pancreatitis, cardiomyopathy, bilateral parotid gland hypertrophy, and Dupuytren's contracture 1, 2

The American Association for the Study of Liver Diseases notes that an AST/ALT ratio >2 is highly suggestive of alcoholic liver disease, with ratios >3 being even more specific 2
AST and ALT typically do not exceed 400 IU/mL in alcohol cirrhosis, and higher values suggest drug-induced liver injury or ischemic hepatitis 3
Measure GGT and mean corpuscular volume (MCV), as both are commonly elevated in chronic alcohol use 1, 2
Obtain complete metabolic panel including serum albumin, bilirubin, prothrombin time/INR, and platelet count to assess liver synthetic function and portal hypertension 1
Normal liver function tests do not exclude significant alcohol-related liver disease 2

Use a liver stiffness cutoff of 12.5 kPa to detect cirrhosis in chronic alcoholic liver disease, with a pooled sensitivity of 0.95 and specificity of 0.71 for cirrhosis detection 4, 5, 6
The 12.5 kPa cutoff was deliberately chosen to minimize false negatives, accepting higher false positives because missing cirrhosis carries greater harm than overdiagnosis 4, 5

Perform ultrasound in all patients with any laboratory abnormalities to assess liver echotexture, exclude biliary obstruction, and evaluate for cirrhosis features 1

Reserve liver biopsy for specific scenarios, such as suspected alcoholic hepatitis requiring specific treatment, discordant or inconclusive non-invasive test results, or suspected coexisting chronic liver disease 1, 2, 3
Use transjugular approach in patients with coagulopathy, thrombocytopenia, or ascites, and percutaneous biopsy under ultrasound guidance is acceptable in patients without coagulopathy 1, 2

Screen for portal hypertension complications, such as esophageal varices, using upper gastrointestinal endoscopy unless platelets >150,000/μL and FibroScan <20 kPa (Baveno criteria) 1, 5, 6
Initiate hepatocellular carcinoma (HCC) screening with liver ultrasound every 6 months in all patients with cirrhosis, as the incidence of HCC in alcoholic cirrhosis ranges from 7-16% at 5 years to 29% at 10 years 7
Assess for extrahepatic complications, such as alcoholic cardiomyopathy, IgA-induced nephropathy, central and peripheral nervous system involvement, chronic pancreatitis, and nutritional deficiencies 7

Physical examination findings in alcoholic liver disease have low sensitivity but higher specificity, meaning their presence helps "rule in" advanced disease, though their absence does not exclude it 8, 9
Physical findings range from completely normal to signs of advanced cirrhosis, and liver palpation may be normal even in the presence of significant alcoholic liver disease 8, 9
No single physical finding or constellation of findings is 100% specific or sensitive for ALD, and considerable heterogeneity exists when different examiners assess the same patient 8, 10

Parotid enlargement is more frequently observed in alcoholic liver disease compared to other liver diseases 8, 9
Dupuytren's contracture is more frequently observed in alcoholic liver disease compared to other liver diseases 8, 9
Signs of feminization, such as gynecomastia, testicular atrophy, and loss of male pattern body hair, are more frequently observed in alcoholic liver disease compared to other liver diseases 8, 9

Hepatic encephalopathy is associated with a higher likelihood of cirrhosis and advanced disease, with a relative risk for 1-year mortality of 4.0 8, 9
Ascites is associated with a higher likelihood of cirrhosis and advanced disease, with a relative risk of 4.0 8, 9
Spider nevi are associated with a higher likelihood of cirrhosis and advanced disease, with a relative risk of 3.3 8, 9
Edema is associated with a higher likelihood of cirrhosis and advanced disease, with a relative risk of 2.9 8, 9
Visible veins across the anterior abdominal wall, indicating collateral circulation, are associated with a higher likelihood of cirrhosis and advanced disease, with a relative risk of 2.2 8, 9
Weakness and muscle wasting are associated with a higher likelihood of cirrhosis and advanced disease, with a relative risk of 2.1 8, 9
Splenomegaly, indicating portal hypertension, is associated with cirrhosis and advanced disease 11, 12

The presence of specific physical examination features, such as hepatic encephalopathy and ascites, carries independent prognostic information regarding 1-year mortality risk, with relative risks of 4.0 each 8, 9
Interpretation of physical findings must be cautious due to significant inter-examiner variability in assessing these features 8, 10

The American Association for the Study of Liver Diseases recommends that the presence of certain physical examination findings, such as hepatic encephalopathy, can help "rule in" advanced cirrhosis, with a relative risk for mortality of 4.0 13
The presence of visible abdominal wall veins, indicating portal hypertension, is associated with a relative risk for mortality of 2.2 13
Peripheral edema is associated with a relative risk for mortality of 2.9 13

Parotid enlargement is more frequently observed in alcoholic cirrhosis than other etiologies 13
Dupuytren's contracture is more frequently observed in alcoholic cirrhosis than other etiologies 13
Signs of feminization, such as gynecomastia, testicular atrophy, and loss of male pattern body hair, are more frequently observed in alcoholic cirrhosis than other etiologies 13

Considerable heterogeneity exists when different examiners assess the same patient, limiting the reliability of physical findings, according to the American Association for the Study of Liver Diseases 13
The presence of specific findings, such as hepatic encephalopathy and ascites, carries independent prognostic information for 1-year mortality, with a relative risk of 4.0 each 13